Colorectal Cancer: Prevention and Management of Metastatic Disease

被引:42
|
作者
Sugarbaker, Paul H. [1 ]
机构
[1] Washington Canc Inst, Washington, DC 20010 USA
关键词
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; PERITONEAL CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; SYSTEMIC CHEMOTHERAPY; SURGICAL-TREATMENT; RANDOMIZED-TRIAL; ADJUVANT THERAPY; MITOMYCIN-C; HIGH-RISK; LIVER;
D O I
10.1155/2014/782890
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This paper compared the similarities and differences of the two most common types of colorectal cancer metastases. The treatment of liver metastases by surgery combined with systemic chemotherapy was explained. The different natural history of liver metastases as compared to peritoneal metastases and the possibility for prevention of peritoneal metastases were emphasized. Perioperative cancer chemotherapy or second-look surgery must be considered as individualized treatments of selected patients who have small volume peritoneal metastases or who are known to be at risk for subsequent disease progression on peritoneal surfaces. However, the fact that peritoneal metastases, when diagnosed in the follow-up of colorectal cancer patients, can be cured with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy cannot be ignored. Careful follow-up and timely intervention in colorectal cancer patients with progressive disease are a necessary part of the management strategies recommended by the multidisciplinary team. After a critical evaluation of the data currently available, these strategies for prevention and management of colorectal metastases are presented as the author's recommendations for a high standard of care. As more information becomes available, modifications may be necessary.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
    Saif, Muhammad Wasif
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2014, 2014
  • [32] Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
    Deming, Dustin A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (07): : 949 - 952
  • [33] Second-line management of metastatic colorectal cancer
    Gallagher, David J.
    Kemeny, Nancy
    CLINICAL COLORECTAL CANCER, 2008, 7 (01) : 25 - 32
  • [34] Australian contemporary management of synchronous metastatic colorectal cancer
    Malouf, Phillip
    Gibbs, Peter
    Shapiro, Jeremy
    Sockler, Jim
    Bell, Stephen
    ANZ JOURNAL OF SURGERY, 2018, 88 (1-2) : 71 - 76
  • [35] The continuum of care: A paradigm for the management of metastatic colorectal cancer
    Goldberg, Richard M.
    Rothenberg, Mace L.
    Van Cutsem, Eric
    Benson, Al B., III
    Blanke, Charles D.
    Diasio, Robert B.
    Grothey, Axel
    Lenz, Heinz-Josef
    Meropol, Neal J.
    Ramanathan, Ramesh K.
    Becerra, Carlos H. Roberto
    Wickham, Rita
    Armstrong, Delma
    Viele, Carol
    ONCOLOGIST, 2007, 12 (01): : 38 - 50
  • [36] Update on the Role of Imaging in Management of Metastatic Colorectal Cancer
    Tirumani, Sree Harsha
    Kim, Kyung Won
    Nishino, Mizuki
    Howard, Stephanie A.
    Krajewski, Katherine M.
    Jagannathan, Jyothi P.
    Cleary, James M.
    Ramaiya, Nikhil H.
    Shinagare, Atul B.
    RADIOGRAPHICS, 2014, 34 (07) : 1908 - 1928
  • [37] Management of BRAF-mutant metastatic colorectal cancer
    Burge, Matthew
    Whitehall, Vicki
    COLORECTAL CANCER, 2016, 5 (04) : 131 - 133
  • [38] Management of metastatic colorectal cancer defining the role of capecitabine
    Wiseman, LR
    Lyseng-Williamson, KA
    DISEASE MANAGEMENT & HEALTH OUTCOMES, 2005, 13 (02) : 137 - 149
  • [39] Management of Peritoneal Disease in Colorectal Cancer
    Welten, Vanessa M.
    Melnitchouk, Nelya
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (03) : 569 - 582
  • [40] Colorectal cancer - Disease management considerations
    Labianca, RF
    Beretta, GD
    Pessi, MA
    DRUGS, 2001, 61 (12) : 1751 - 1764